AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 172 min read$KMTS

Webster Brian Daniel sold $312K of KMTS

Webster Brian Daniel (See Remarks) sold 15,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $20.81 ($0.31M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Jun 17, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale of 15,000 shares by an officer/director under a pre-arranged Rule 10b5-1 plan; no new company fundamentals are stated.

02

Market read

Traders may treat this as low-signal insider activity; without accompanying fundamental news, it is unlikely to drive a sustained repricing.

03

What to watch

The article doesn’t disclose whether other insiders sold/bought around the same window, nor does it provide context on total insider holdings beyond the post-transaction figure.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17; sale dated 2026-06-15

Background

This is an SEC Form 4 insider transaction for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), reported via EDGAR.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows officer/director Webster Brian Daniel sold 15,000 KMTS shares on 2026-06-15 for about $312K under a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The disclosure is a routine Form 4 sale with stated 10b5-1 pre-arrangement; no new operational, financial, or regulatory catalyst is provided.

Market effects

Sector

Minimal—this is company-specific insider transaction disclosure with no sector-wide datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can still coincide with internal expectations of near-term volatility or liquidity needs, so traders may watch for follow-on selling or unusual volume.

Key entities

  • equity issuer
    KMTS

    Subject of the Form 4 insider sale disclosure.

  • insider
    Webster Brian Daniel

    Officer/director who sold 15,000 shares on 2026-06-15 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min